Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMGN ImmunoGen (IMGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About ImmunoGen Stock (NASDAQ:IMGN) 30 days 90 days 365 days Advanced Chart Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get ImmunoGen alerts:Sign Up Key Stats Today's Range$31.23▼$31.2350-Day Range$31.23▼$31.2352-Week Range$3.61▼$31.25Volume40 shsAverage Volume8.78 million shsMarket Capitalization$8.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Read More… We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address IMGN Stock News HeadlinesPureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial OfficerNovember 5, 2024 | finance.yahoo.comSeaport Therapeutics Names Lauren White as Chief Financial OfficerNovember 5, 2024 | finance.yahoo.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.December 10, 2024 | Behind the Markets (Ad)Artisan International Small-Mid InstlOctober 25, 2024 | morningstar.comArtisan International Small-Mid AdvisorOctober 25, 2024 | morningstar.comPolaris Global Equity Composite Q1 2024 CommentaryApril 25, 2024 | seekingalpha.comLazard posts first-quarter profit on deals, assets boostApril 25, 2024 | investing.com3 Potential Biopharma Buyout TargetsApril 23, 2024 | seekingalpha.comSee More Headlines IMGN Stock Analysis - Frequently Asked Questions How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The firm's quarterly revenue was up 485.9% compared to the same quarter last year. Does ImmunoGen have any subsidiaries? ImmunoGen subsidiaries include these companies: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp.. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), General Electric (GE), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings7/31/2023Today12/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio390.38 P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$287.61 million Price / Sales28.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book43.99Miscellaneous Outstanding Shares266,264,000Free Float252,764,000Market Cap$8.32 billion OptionableOptionable Beta1.18 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:IMGN) was last updated on 12/10/2024 by MarketBeat.com Staff From Our PartnersCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.